Webinar – Jueves, 21 de mayo, 10:00 horas

New research avenues for pancreatic cancer

Dr. Bruno Sainz
Ramón y Cajal Investigator, Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC-UAM, Area 3
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Autónoma University of Madrid (UAM), Department of Biochemistry


Link: https://conecta2.csic.es/b/nie-t2q-7nc

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth most frequent cause of cancer-related deaths worldwide, and is projected to become the second deadliest cancer by 2030. Patients are typically diagnosed at late stages, when therapeutic intervention only slightly improves overall survival beyond 6 months and very rarely result in long-term progression-free survival. Dr. Sainz will discuss some of the current advancements made, at the level of basic research, to better understand this devastating disease. In particular, he will highlight and discuss advances made at the level of genomics, drug therapy, tumor heterogeneity, cancer stem cells, personalised medicine and cancer metabolism.


Dr. Sainz received his PhD in Microbiology and Immunology from Tulane University in New Orleans, Louisiana in May 2005. After receiving his PhD he completed a PostDoctoral Fellowship at the Scripps Research Institute in La Jolla, CA EEUU under the supervision of Dr. Francis Chisari. While at Scripps he worked on developing an in vitro system to study Hepatitis C Virus replication in vitro. In 2006 he moved to the University of Illinois at Chicago and during his second post doc he discovered a new Hepatitis C Virus entry receptor and a clinically approved drug (Zetia) that could inhibit HCV entry in vitro and in vivo. This work was published in Nature Medicine in 2011. In November 2011, I moved to Spain and joined the CNIO as a Staff Scientist in the CSC laboratory led by Dr. Christopher Heeschen. During this time he participated in several cutting edge projects and published my work on CSCs and the tumor microenvironment in numerous high impact journals. In 2014, after being awarded a Ramón y Cajal merit award, he started his own research group at the Universidad Autónoma de Madrid. He is currently a Ramón y Cajal Investigator in the Department of Biochemistry, Group Leader in the Department of Cancer Biology at the Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC-UAM and Group Leader of the Células Madre de Cáncer y Microambiente Inflamatorio Grupo at the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). He has published over 60 publications in high impact journals including Nature Medicine, Nature Methods, PNAS, Gut and Cancer Cell, and Nature Communications and has been awarded several US (Cancer Research Institute, Concern Foundation), Spanish (ISCIII, AECC, ACANPAN, FERO Foundation), European (EuroNanoMed) and Private grants and contracts. His main research focusses on deciphering the role of cancer stem cells in pancreatic ductal adenocarcinoma.